Maria Holtze
Overview
Explore the profile of Maria Holtze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
329
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu X, Holtze M, Powell S, Terrando N, Larsson M, Persson A, et al.
Brain Behav Immun
. 2013 Oct;
36:80-9.
PMID: 24140727
Exposure to infections in early life is considered a risk-factor for developing schizophrenia. Recently we reported that a neonatal CNS infection with influenza A virus in mice resulted in a...
2.
Linderholm K, Powell S, Olsson E, Holtze M, Snodgrass R, Erhardt S
Int J Tryptophan Res
. 2011 Nov;
3:1-12.
PMID: 22084584
Kynurenic acid (KYNA) is an endogenous metabolite of tryptophan. Studies have revealed increased brain KYNA levels in patients with schizophrenia. Prepulse inhibition (PPI) is a behavioral model for sensorimotor gating...
3.
Holtze M, Saetre P, Engberg G, Schwieler L, Werge T, Andreassen O, et al.
J Psychiatry Neurosci
. 2011 Jun;
37(1):53-7.
PMID: 21693093
Background: Patients with schizophrenia show increased brain and cerebrospinal fluid (CSF) concentrations of the endogenous N-methyl-D-aspartate receptor antagonist kynurenic acid (KYNA). This compound is an end-metabolite of the kynurenine pathway,...
4.
Holtze M, Saetre P, Erhardt S, Schwieler L, Werge T, Hansen T, et al.
Schizophr Res
. 2010 Oct;
127(1-3):270-2.
PMID: 21030213
No abstract available.
5.
Linderholm K, Skogh E, Olsson S, Dahl M, Holtze M, Engberg G, et al.
Schizophr Bull
. 2010 Aug;
38(3):426-32.
PMID: 20729465
Background: The kynurenic acid (KYNA) hypothesis for schizophrenia is partly based on studies showing increased brain levels of KYNA in patients. KYNA is an endogenous metabolite of tryptophan (TRP) produced...
6.
Asp L, Holtze M, Powell S, Karlsson H, Erhardt S
Int J Neuropsychopharmacol
. 2009 Jul;
13(4):475-85.
PMID: 19607757
Epidemiological studies suggest that early life infections may contribute to the development of neuropsychiatric disorders later in life. Experimental studies employing infections during neonatal life support this notion by reporting...
7.
Olsson S, Andersson A, Linderholm K, Holtze M, Nilsson-Todd L, Schwieler L, et al.
Int J Neuropsychopharmacol
. 2008 Sep;
12(4):501-12.
PMID: 18796185
Kynurenic acid (KYNA) is an endogenous compound implicated in the pathophysiology of schizophrenia. This tryptophan metabolite antagonizes both the N-methyl-D-aspartate (NMDA) receptors and the nicotinic alpha7* receptors at micromolar concentrations....
8.
Holtze M, Asp L, Schwieler L, Engberg G, Karlsson H
J Neurosci Res
. 2008 Jul;
86(16):3674-83.
PMID: 18655201
Glutamatergic NMDA (N-methyl D-aspartate) receptors play a critical role in brain development and neurotransmission. Kynurenic acid, an end product of tryptophan degradation along the kynurenine pathway, is an endogenous NMDA...